CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, with a primary emphasis on combating serious infections. The company’s core product is DefenCath, an antimicrobial catheter lock solution containing taurolidine and heparin, which is indicated to reduce catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis. In August 2025, the company acquired Melinta Therapeutics, LLC, expanding its portfolio to include six marketed infectious disease products: REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, and BAXDELA, as well as the cardiovascular product TOPROL-XL. These products address serious gram-positive, gram-negative, and fungal infections within hospitals, emergency departments, outpatient clinics, and home infusion care settings. The company serves the U.S. market, with DefenCath supplied to outpatient dialysis clinics and inpatient hospitals. CorMedix is pursuing expanded indications for DefenCath in patients receiving total parental nutrition and for REZZAYO in the prophylaxis of invasive fungal infections in immune-compromised patients.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage cormedix.com
Sector Healthcare IR page cormedix.com/investors
Tags
anti-infectives, catheter lock solutions, hemodialysis, infectious disease, antibiotics, antifungals, hospital care, outpatient clinics, DefenCath, Melinta Therapeutics, REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, TOPROL-XL
Press page cormedix.com/press-releases

Metrics

Valuation  
Market cap $ 387.849M
Market cap (USD) $ 387.849M
P/E 6.68
PEG —
P/BV 0.84
P/S 0.93
P/OCF 1.24
P/FCF 1.26
Dividend yield —
Turnover / mcap —
Returns  
ROE 66.6%
ROI 29.7%
ROIC 27.3%
Profit margin 52.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 35.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 45
Quality score 80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 311.709M 43.472M — 65.408K 190.936K 239.231K 283.266K 429.797K 329.327K 224.105K 210.13K 189.274K 2.001K — — —
Net profit 163.055M -17.93M -46.339M -29.702M -28.21M -22.028M -16.433M -26.83M -33.01M -24.644M -18.188M -20.453M -9.133M -3.426M -6.711M -10.905M
Free cash flow 172.786M -50.73M -38.737M -24.576M -22.581M -22.08M -15.089M -23.749M -28.739M -22.324M -12.542M -6.346M -3.654M -2.276M -6.298M -3.679M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 11.63 8.1 3.76 4.22 4.55 7.43 7.28 1.21 0.48 1.58 2.66 1.91 0.74 0.45 0.32 1.3
Price performance 12m 0.44 1.15 -0.11 -0.07 -0.39 0.02 5.02 1.52 -0.7 -0.41 0.39 1.58 0.64 0.41 -0.75 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 12,014 64,148 10,904 — — — — — 51.7M 171M
↳ YoY growth -96.2% +433.9% -83.0% +231.5%
↳ 5y CAGR +36.1%
Lease liabilities (USD) — — 0.00 2,678 1.03M 923,801 802,433 667,632 517,013 4.29M
Cash and deposits (USD) 8.06M 10.4M 17.6M 16.4M 41.9M 53.3M 43.1M 43.6M 40.7M 145M
Intangible assets (USD) — — — — — — — — 1.84M 379M
Right-of-use assets (USD) — — 6,000 4,690 1.01M 899,505 775,085 640,278 492,697 3.02M
Cash flow detail
Operating cash flow (USD) -22.3M -28.6M -23.7M -15.1M -22M -21.2M -24.4M -38.4M -50.6M 175M
Purchases of property, plant and equipment (USD) -58,723 -151,988 48,893 -36,571 -112,638 -1.43M -219,360 -327,300 -115,730 -2.26M
Change in receivables (cash effect) (USD) 307,774 -47,599 -51,986 10,631 -3,089 -44,080 42,143 — -51.8M -90.9M
Change in inventories (cash effect) (USD) 79,836 -100,461 -165,679 59,285 149,597 145,456 3,008 -2.11M -5.49M -3.48M
Change in payables (cash effect) (USD) -63,586 157,525 782,062 -1.56M 103,333 1.08M -6,566 2.08M -2.56M 3.33M
Interest paid (cash effect) (USD) -1,197 -5,619 -1,873 -12,552 -33,226 -15,943 -26,516 -34,296 -36,405 -17,000
Income taxes paid (cash effect) (USD) — — — — — — — — -6,000 -62,000
Share-based compensation (USD) 1.34M 1.66M 1.11M 2.44M 2.5M 5.04M 4.07M 5.49M 6.13M 13.8M
Operating cash flow before change in receivables (USD) -22.6M -28.5M -23.6M -15.1M -22M -21.1M -24.4M — 1.18M 266M
Free cash flow (OCF - PPE - intangibles) (USD) -22.3M -28.7M -23.7M -15.1M -22.1M -22.6M -24.6M -38.7M -50.7M 173M
Income detail
Research and development expense (USD) 15.7M 24.5M 18.8M 11.1M 13.4M 13.1M 10.7M 13.2M 3.94M 19.3M
↳ 5y CAGR +30.9% +83.2% +72.7% +53.0% +16.3% -3.6% -15.3% -6.9% -18.6% +7.6%
Total comprehensive income (USD) -24.6M -33M -26.8M -16.4M -22M -28.2M -29.7M -46.3M -17.9M -88,000
Comprehensive income to owners (USD) -24.6M -33M -26.8M -16.4M -22M -28.2M -29.7M -46.3M -17.9M -88,000
Reported Mar 16, 2017 Mar 19, 2018 Mar 16, 2020 Nov 5, 2020 Mar 30, 2021 Mar 29, 2022 Mar 30, 2023 Mar 12, 2024 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

CorMedix Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

On November 12, 2026, CorMedix Inc. (the “Company” or “CorMedix”) hosted a conference call and webcast for investors to discuss its financial results for the quarter ended September 30, 2026. A copy of the transcript of the conference call is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Additional Information and Where to Find It

In connection with the Proposed Acquisition (as defined below), Heron Therapeutics, Inc. (“Heron”) intends to file with the SEC a proxy statement on Schedule 14A. Each of CorMedix and Heron has and may file relevant documents with the SEC regarding the Proposed Acquisition. This Current Report on Form 8-K is not a substitute for the proxy statement or any other document that CorMedix or Heron may file with the SEC. Heron will mail the definitive proxy statement to its stockholders. INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION.

‒ Recently announced acquisition of assets of Heron Therapeutics ‒

‒ Q3 2026 consolidated revenue of $54.5 million ‒

‒ Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million ‒

‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒

‒ Conference call scheduled for today at 8:30 a.m. Eastern Time ‒

Parsippany, NJ – November 12, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the third quarter ended September 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

•CorMedix and Heron Therapeutics, Inc. ("Heron") announced on November 9, 2026, that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron. CorMedix believes the transaction will be immediately accretive to earnings and free cash flow upon closing, which it anticipates in the first quarter of 2027, subject to approval by Heron’s stockholders, regulatory clearance and other customary closing conditions.

CorMedix Inc. — Regulation FD Disclosure Bull 5 Bear 0 M&A

On November 9, 2026, CorMedix Inc. (the “Company” or “CorMedix”) and Heron Therapeutics, Inc. (“Heron”) announced that the Company has entered into a definitive asset purchase agreement with Heron under which the Company will acquire substantially all of the assets of Heron. In connection with the announcement, the Company hosted a conference call and webcast for investors on November 9, 2026, and made available an investor presentation regarding the transaction. A copy of the transcript of the conference call is furnished with this Current Report on Form 8-K as Exhibit 99.1, and a copy of the investor presentation is furnished with this Current Report on Form 8-K as Exhibit 99.2, each of which is incorporated by reference herein.

Additional Information and Where to Find It

In connection with the Proposed Acquisition (as defined below), CorMedix has and may file relevant documents with the SEC regarding the Proposed Acquisition. This Current Report on Form 8-K is not a substitute for any other document that CorMedix may file with the SEC.

Prompts

CorMedix Inc. (ticker CRMD), listed in United States.

ETFs Holding CorMedix Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.24% 8,657 $ 67.957K Jun 30, 2026
AFSM 0.21% 64,731 $ 312.003K Nov 16, 2026
PSC 0.06% 187,228 $ 1.47M Jun 30, 2026
BSVO 0.05% 282,794 $ 1.32M Nov 18, 2026
AVUV 0.04% 2,899,428 $ 13.975M Nov 16, 2026
RESM 0.03% 124 $ 973.40 Jun 30, 2026
AVSC 0.01% 93,868 $ 452.444K Nov 16, 2026
AVUS 0.00% 68,753 $ 331.389K Nov 16, 2026
AVUQ 0.00% 2,326 $ 11.211K Nov 16, 2026